HK1102021A1 - Pharmaceutical composition for oral administration of a pyrazol-3- carboxamide derivative - Google Patents

Pharmaceutical composition for oral administration of a pyrazol-3- carboxamide derivative

Info

Publication number
HK1102021A1
HK1102021A1 HK07106763.5A HK07106763A HK1102021A1 HK 1102021 A1 HK1102021 A1 HK 1102021A1 HK 07106763 A HK07106763 A HK 07106763A HK 1102021 A1 HK1102021 A1 HK 1102021A1
Authority
HK
Hong Kong
Prior art keywords
pyrazol
pharmaceutical composition
oral administration
carboxamide derivative
carboxamide
Prior art date
Application number
HK07106763.5A
Other languages
English (en)
Inventor
Thierry Breul
Jean Claude Gautier
Olivier Saslawski
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HK1102021A1 publication Critical patent/HK1102021A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK07106763.5A 2003-11-10 2007-06-25 Pharmaceutical composition for oral administration of a pyrazol-3- carboxamide derivative HK1102021A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0313259A FR2861992B1 (fr) 2003-11-10 2003-11-10 Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
PCT/FR2004/002875 WO2005046690A1 (fr) 2003-11-10 2004-11-09 Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3­carboxamide

Publications (1)

Publication Number Publication Date
HK1102021A1 true HK1102021A1 (en) 2007-11-02

Family

ID=34508418

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07106763.5A HK1102021A1 (en) 2003-11-10 2007-06-25 Pharmaceutical composition for oral administration of a pyrazol-3- carboxamide derivative

Country Status (28)

Country Link
US (2) US20060264469A1 (es)
EP (1) EP1691808B1 (es)
JP (1) JP4767171B2 (es)
KR (1) KR20060108668A (es)
CN (1) CN100528158C (es)
AR (1) AR047237A1 (es)
AT (1) ATE429227T1 (es)
AU (1) AU2004289086A1 (es)
BR (1) BRPI0416341A (es)
CA (1) CA2544413A1 (es)
CY (1) CY1110478T1 (es)
DE (1) DE602004020797D1 (es)
DK (1) DK1691808T3 (es)
ES (1) ES2325373T3 (es)
FR (1) FR2861992B1 (es)
HK (1) HK1102021A1 (es)
HR (1) HRP20090393T1 (es)
IL (1) IL175556A (es)
MA (1) MA28419B1 (es)
NO (1) NO20062609L (es)
NZ (1) NZ547763A (es)
PL (1) PL1691808T3 (es)
PT (1) PT1691808E (es)
RU (1) RU2321404C1 (es)
SI (1) SI1691808T1 (es)
TW (1) TWI280129B (es)
WO (1) WO2005046690A1 (es)
ZA (1) ZA200604451B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
WO2009024590A2 (en) * 2007-08-21 2009-02-26 Basilea Pharmaceutica Ag Antifungal composition
MY158809A (en) * 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
WO2012071043A1 (en) * 2010-11-24 2012-05-31 Pharmaceutics International, Inc. Self micro-emulsifying drug delivery system with increased bioavailability

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059691A (en) * 1990-01-22 1991-10-22 American Cyanamid Company N-((dialkylamino)methylene)-substituted pyrazolo (1,5-A)-pyrimidine-3-carboxamides and N-((dialkylamino)methylene)-substituted-4,5-dihydropyrazolo-(1,5-A)-pyrimidine-3-carboxamides
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
EP1033128B2 (en) * 1993-09-28 2011-11-23 R.P. Scherer GmbH Soft gelatin capsule manufacture
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
JPH11504028A (ja) * 1995-04-24 1999-04-06 イースム リサーチ ディベロップメント カンパニー オブ ザ ヒーブル ユニバーシティ オブ エルサレム 油／水エマルジョンを作り出す自己乳化性配合物
JPH11505257A (ja) * 1995-05-19 1999-05-18 アボツト・ラボラトリーズ 親油性薬物の自己乳化性製剤
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
TW495509B (en) * 1997-03-14 2002-07-21 Otsuka Pharma Co Ltd Novel pyrimidine derivative
FR2761265B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
FR2761266B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
US6617426B1 (en) * 1999-06-22 2003-09-09 Merck & Co Inc Cysteinyl protease inhibitors
JP2001151669A (ja) * 1999-11-24 2001-06-05 Nippon Kayaku Co Ltd 経口用自己乳化製剤
YU43702A (sh) * 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
JP2005523295A (ja) * 2002-03-01 2005-08-04 ノバガリ、ファルマ、エスアー 難溶性薬剤の自己乳化型薬物送達システム
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process

Also Published As

Publication number Publication date
AR047237A1 (es) 2006-01-11
CA2544413A1 (fr) 2005-05-26
JP4767171B2 (ja) 2011-09-07
US20060264469A1 (en) 2006-11-23
RU2006120447A (ru) 2007-12-20
AU2004289086A1 (en) 2005-05-26
KR20060108668A (ko) 2006-10-18
DE602004020797D1 (de) 2009-06-04
RU2321404C1 (ru) 2008-04-10
NZ547763A (en) 2009-08-28
FR2861992B1 (fr) 2007-07-20
WO2005046690A1 (fr) 2005-05-26
TWI280129B (en) 2007-05-01
PL1691808T3 (pl) 2009-09-30
DK1691808T3 (da) 2009-08-03
IL175556A0 (en) 2008-04-13
CN100528158C (zh) 2009-08-19
CY1110478T1 (el) 2015-04-29
EP1691808B1 (fr) 2009-04-22
FR2861992A1 (fr) 2005-05-13
HRP20090393T1 (en) 2009-08-31
SI1691808T1 (sl) 2009-10-31
ZA200604451B (en) 2007-10-31
ES2325373T3 (es) 2009-09-02
EP1691808A1 (fr) 2006-08-23
CN1925856A (zh) 2007-03-07
ATE429227T1 (de) 2009-05-15
IL175556A (en) 2010-11-30
PT1691808E (pt) 2009-07-14
NO20062609L (no) 2006-06-06
JP2007516960A (ja) 2007-06-28
TW200524597A (en) 2005-08-01
US20090004261A1 (en) 2009-01-01
BRPI0416341A (pt) 2007-02-27
MA28419B1 (fr) 2007-02-01

Similar Documents

Publication Publication Date Title
ZA200605631B (en) Directly compressible pharmaceutical composition for the oral administration of CCI-779
PL368636A1 (en) Pharmaceutical dosage forms of epothilones for oral administration
IL166489A (en) Oral dosage form in single-dose administration containing at least two layers for the administration and use of flipridone
PL356358A1 (en) Solid dosage form of someticone for oral administration
EP1757273A4 (en) PREPARATION FOR ORAL ADMINISTRATION
HK1085131A1 (en) Solid drug for oral use
AU2003303633A8 (en) Fast dissolving films for oral administration of drugs
AU2003246978A1 (en) Pharmaceutical compositions comprising cyclosporin for oral administration
PL372773A1 (en) Oral administration of epothilones
IL166337A0 (en) Oral administration of calctionin
AU2003245504A1 (en) Pharmaceutical compositions for drugs having ph-dependentsolubility
IL161143A0 (en) A flash-melt pharmaceutical oral dosage composition
HK1072194A1 (en) Oral dosage form for controlled drug release
EP1683525A4 (en) PREPARATION OF SUSTAINED RELEASE PHENYLALANINE DERIVATIVES FOR ORAL ADMINISTRATION
HK1102021A1 (en) Pharmaceutical composition for oral administration of a pyrazol-3- carboxamide derivative
HK1083768A1 (en) Sustained-release pharmaceutical composition for lung administration
AU2003284786A8 (en) Microemulsion composition for oral administration of biphenyldimethyldicarboxylate
EP1626697A4 (en) PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION WITH LITHIUM CARBONATE
AU2003251643A1 (en) Pharmaceutical compositions containing keto-acids for endoperitoneal administration
ZA200603126B (en) Pharmaceutical compositions for therapeutic use
PL373776A1 (en) Oral pharmaceutical compound
AU2003244092A1 (en) 1ss-METHYLCARBAPENEM DERIVATIVE FOR ORAL ADMINISTRATION
HU0203985D0 (en) Use of a pharmaceutical composition for alleviating side effect of a disease
AU2003254672A8 (en) Dual-spike release formulation for oral drug delivery
GB0218994D0 (en) Oral pharmaceutical compositions

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131109